An application of a new planar positron imaging system (PPIS) in a small animal: MPTP-induced parkinsonism in mouse

Annals of Nuclear Medicine

Volumn 18, Issue 5, 2004, Pages 427-431

  Takamatsu, Hiroyuki ^a,d   Kakiuchi, Takeharu ^b   Noda, Akihiro ^a   Uchida, Hiroshi ^b   Nishiyama, Shingo ^b   Ichise, Rikiya ^a   Iwashita, Akinori ^c   Mihara, Kayoko ^c   Yamazaki, Shunji ^c   Matsuoka, Nobuya ^c   Tsukada, Hideo ^b   Nishimura, Shintaro ^a  

^a Medical and Pharmacological Research Center Foundation   (Japan)

^b CENTRAL RESEARCH LABORATORY   (Japan)

^c ASTELLAS PHARMA INC   (Japan)

^d Medical and Pharmacological Research Center Foundation   (Japan)

Author keywords

Mouse; MPTP; Planar positron imaging system

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CARBON 11; CARBON 14; DOPAMINE 1 RECEPTOR; DOPAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC VALUE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGING SYSTEM; MALE; MOUSE; NONHUMAN; PARKINSONISM; PLANAR POSITRON IMAGING SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 4644289722     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984486     Document Type: Article

References (28)

1. Chatziioannou AF, Cherry SR, Shao Y, Silverman RW, Meadors K, Farquhar TH, et al. Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J Nucl Med 1999; 40: 1164-1175.
2. Chatziioannou A, Tai YC, Doshi N, Cherry SR. Detector development for microPET II: a 1 microl resolution PET scanner for small animal imaging. Phys Med Biol 2001; 46: 2899-2910.
3. Tai C, Chatziioannou A, Siegel S, Young J, Newport D, Goble RN, et al. Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol 2001; 46: 1845-1862.
4. Chatziioannou AF. Molecular imaging of small animals with dedicated PET tomographs. Eur J Nucl Med Mol Imaging 2002; 29: 98-114.
5. Uchida H, Okamoto T, Ohmura T, Shimizu K, Satoh N, Koike T, et al. A compact planar positron imaging system. Nucl Instr and Meth (A) 2003; 516: 564-574.
6. Kitamura Y, Itano Y, Kubo T, Nomura Y. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. J Neuroimmunol 1994; 50: 221-224.
7. Mayer RA, Walters AS, Heikkila RE. 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) administration to C57-black mice leads to parallel decrements in neostriatal dopamine content and tyrosine hydroxylase activity. Eur J Pharmacol 1986; 120: 375-377.
8. Araki T, Kumagai T, Matsubara M, Ido T, Imai Y, Itoyama Y. Protective effect of riluzole on MPTP-induced depletion of dopamine and its metabolite content in mice. Metab Brain Dis 2000; 15: 193-201.
9. Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse 1993; 14: 184-194.
10. Graham WC, Clarke CE, Boyce S, Sambrook MA, Crossman AR, Woodruff GN. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res 1990; 514: 103-110.
11. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-980.
12. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985; 36: 2503-2508.
13. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993; 61: 1191-1206.
14. Tolwani RJ, Jakowec MW, Petzinger GM, Green S, Waggie K. Experimental models of Parkinson's disease: insights from many models. Lab Anim Sci 1999; 49: 363-371.
15. 11C]SCH23390: a test-retest analysis. J Cereb Blood Flow Metab 2001; 21: 1133-1145.
16. Suhara T, Fukuda H, Inoue O, Itoh T, Suzuki K, Yamasaki T, et al. Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology 1991; 103: 41-45.
17. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N, et al. Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR 12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res 1999; 849: 85-96.
18. Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T. Dose-response and duration effects of acute administrations of cocaine and GBR12909 on dopamine synthesis and transporter in the conscious monkey brain: PET studies combined with microdialysis. Brain Res 2000; 860: 141-148.
19. 11C]-CFT and PET in a primate model of parkinsonism. Neuroreport 1992; 3: 265-268.
20. 11C]WIN 35,428. Synapse 1993; 15: 130-142.
21. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997; 69: 1322-1325.
22. Iwata S, Shimizu T, Nomoto M, Fukuda T. Characteristic upregulation of dopamine D1-receptor in rat striatum after 6-hydroxydopamine treatment. Jpn J Pharmacol 1996; 71: 255-258.
23. Alexander GM, Brainard DL, Gordon SW, Hichens M, Grothusen JR, Schwartzman RJ. Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates. Brain Res 1991; 547: 181-189.
24. Laihinen AO, Rinne JO, Ruottinen HM, Nagren KA, Lehikoinen PK, Oikonen VJ, et al. PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. J Nucl Med 1994; 35: 1916-1920.
25. Rinne JO, Laihinen A, Nagren K, Bergman J, Solin O, Haaparanta M, et al. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J Neurosci Res 1990; 27: 494-499.
26. Shinotoh H, Inoue O, Hirayama K, Aotsuka A, Asahina M, Suhara T, et al. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 1993; 56: 467-472.
27. Marshall JF, Navarrete R, Joyce JN. Decreased striatal D1 binding density following mesotelencephalic 6-hydroxydopamine injections: an autoradiographic analysis. Brain Res 1989; 493: 247-257.
28. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997; 49: 717-723.